AR055106A1 - Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa - Google Patents

Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa

Info

Publication number
AR055106A1
AR055106A1 ARP060103357A ARP060103357A AR055106A1 AR 055106 A1 AR055106 A1 AR 055106A1 AR P060103357 A ARP060103357 A AR P060103357A AR P060103357 A ARP060103357 A AR P060103357A AR 055106 A1 AR055106 A1 AR 055106A1
Authority
AR
Argentina
Prior art keywords
release
levodopa
extended
tablet
carbidopa
Prior art date
Application number
ARP060103357A
Other languages
English (en)
Inventor
Marcelo F Befumo
Marcelo Ricci
Ethel C Feleder
Glenn A Meyer
Joaquina Faour
Juan A Vergez
Original Assignee
Osmotica Pharmaceutical Argent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Pharmaceutical Argent filed Critical Osmotica Pharmaceutical Argent
Publication of AR055106A1 publication Critical patent/AR055106A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

Un comprimido que proporciona un comprimido de liberacion extendida que contiene una forma de liberacion extendida de carbidopa y una forma de liberacion extendida de levodopa. El comprimido opcionalmente además comprende una composicion de liberacion inmediata o rápida de carbidopa y/o levodopa. La composicion de liberacion extendida en el comprimido excluye un polímero de control de velocidad de liberacion, y un recubrimiento de control de la velocidad de liberacion; sin embargo, la liberacion de la carbidopa y/o levodopa es independientemente de forma opcional retrasada por un período de retraso.. También un comprimido que posee una forma de liberacion extendida de levodopa y una forma de liberacion rápida o inmediata de carbidopa. Un comprimido puede contener levodopa presente en una forma de liberacion extendida y una forma de liberacion rápida o inmediata. y carbidopa presente en una forma de liberacion extendida y en forma de liberacion rápida o inmediata. El comprimido es usado para tratar la enfermedad de Parkinson y otros desordenes, enfermedades o síndromes relacionados con el movimiento. Reivindicacion 1: Una composicion farmacéutica solida de liberacion extendida que consiste esencialmente de: una mezcla de liberacion extendida que comprende una cantidad terapéuticamente efectiva de levodopa y una cantidad terapéuticamente efectiva de carbidopa, un ácido orgánico, una sal o un carbohidrato, y opcionalmente uno o más otros excipientes, en donde la levodopa y a carbidopa son liberadas lentamente y sustancialmente de forma continua durante un período de 1 a 4 horas cuando el comprimido es expuesto a un medio acuoso, y en donde el comprimido excluye un polímero e control de la velocidad de liberacion y un recubrimiento de control de la velocidad de liberacion. Reivindicacion 10: Un comprimido multicapa de liberacion extendida que comprende: una composicion de liberacion inmediata que comprende levodopa y carbidopa, una composicion de liberacion extendida que comprende levodopa y opcionalmente carbidopa; y una composicion de liberacion retasada, en donde la composicion de liberacion retrasada es un recubrimiento de liberacion retrasada que rodea a la composicion de liberacion extendida o la composicion de liberacion retrasada es un material de liberacion retrasada incluido dentro de la composicion de liberacion extendida, y la levodopa y carbidopa son liberadas sustancialmente de forma continua durante un período de a 1 4 horas luego de la exposicion del comprimido a un ambiente acuoso.
ARP060103357A 2005-08-05 2006-08-02 Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa AR055106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70583905P 2005-08-05 2005-08-05

Publications (1)

Publication Number Publication Date
AR055106A1 true AR055106A1 (es) 2007-08-08

Family

ID=38458530

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103357A AR055106A1 (es) 2005-08-05 2006-08-02 Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa

Country Status (11)

Country Link
US (1) US20070275060A1 (es)
EP (1) EP1909768A1 (es)
JP (1) JP2009502987A (es)
KR (1) KR20080033354A (es)
CN (1) CN101516351A (es)
AR (1) AR055106A1 (es)
AU (1) AU2006345054A1 (es)
BR (1) BRPI0614091A2 (es)
CA (1) CA2614389A1 (es)
MX (1) MX2008001711A (es)
WO (1) WO2008000194A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2227224A2 (en) * 2007-12-17 2010-09-15 Pharmathen S.a. Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof
EP2234963B1 (en) 2007-12-28 2020-04-08 Impax Laboratories, LLC Controlled release formulations of levodopa and uses thereof
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
UA106877C2 (uk) * 2008-08-22 2014-10-27 Вокхардт Рісерч Сентер Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення
US8840934B2 (en) * 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
EP2419508A4 (en) * 2009-04-17 2012-11-14 Somalabs Inc METHOD OF INDUCING REWARD RESPONSE BY MODULATION OF DOPAMINERGIC SYSTEMS IN THE CENTRAL NERVOUS SYSTEM
US20130179187A1 (en) 2012-01-06 2013-07-11 Molecular Health Systems and methods for de-risking patient treatment
WO2014006571A2 (en) * 2012-07-02 2014-01-09 Ranbaxy Laboratories Limited Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
CN102755310B (zh) * 2012-07-26 2016-06-15 温天文 一种含有左旋多巴的组合物药物制剂
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
CN102924652B (zh) * 2012-11-26 2014-07-23 无锡朗立药业有限公司 聚丙烯酸树脂ⅳ的精制方法
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
MX369315B (es) 2013-10-07 2019-11-05 Impax Laboratories Inc Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos.
US9808478B2 (en) * 2015-04-17 2017-11-07 Steven Loyd Control release of fat soluble antioxidants from an oral formulation and method
EA036784B1 (ru) 2016-08-18 2020-12-21 Илько Илач Санайи Ве Тиджарет Аноним Ширкети Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP2021517128A (ja) * 2018-03-29 2021-07-15 アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー レボドパ分割用量組成物および使用
EP4025195A4 (en) * 2019-09-06 2023-10-04 Triastek, Inc. ORAL DOSAGE FORMS OF DRUG HAVING A DESIRED PK PROFILE AND METHODS OF DESIGN AND PRODUCTION THEREOF
CN113616621A (zh) * 2021-08-19 2021-11-09 北京世桥生物制药有限公司 一种左旋多巴和卡比多巴控释制剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
DE3437694A1 (de) * 1984-10-15 1986-04-17 Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim Verwendung einer substanz als sedativum
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5624960A (en) * 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
CA2599384A1 (en) * 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of parkinson's disease
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment

Also Published As

Publication number Publication date
BRPI0614091A2 (pt) 2011-03-09
EP1909768A1 (en) 2008-04-16
CA2614389A1 (en) 2008-01-03
US20070275060A1 (en) 2007-11-29
JP2009502987A (ja) 2009-01-29
CN101516351A (zh) 2009-08-26
KR20080033354A (ko) 2008-04-16
AU2006345054A1 (en) 2008-01-03
WO2008000194A1 (en) 2008-01-03
MX2008001711A (es) 2008-04-07

Similar Documents

Publication Publication Date Title
AR055106A1 (es) Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
CL2020002026A1 (es) Inhibidor de fap.
BR112021023923A2 (pt) Agonistas de receptor de peptídeo 1 similares a glucagon
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
GT200600089A (es) Compuestos organicos
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
SV2009003146A (es) Moduladores del metabolismo y tratamiento de los transtornos metabolicos ref. 20750-0033sv1 (137. sv1.pct)
PE20120599A1 (es) Metodo para producir material de sabor
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
ECSP088627A (es) Compuestos para el tratamiento de trastornos inflamatorios
CY1113068T1 (el) Φαρμακευτικες συνθεσεις ριφαξιμινης
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
PE20060872A1 (es) Colorantes de cianina en el diagnostico de enfermedades proliferativas
UY30986A1 (es) Derivados fluorinados de deferiprona
WO2009137827A3 (en) Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
NZ595189A (en) Combination therapy with thiocolchicine derivatives
EA201600089A1 (ru) Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
PE20080907A1 (es) Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
BRPI0606322A2 (pt) formulações intravenosas de inibidores de pde-5
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7

Legal Events

Date Code Title Description
FA Abandonment or withdrawal